Edison Investment Research - Orexo AB (ORX) Good things come in threes

Report

Edison Investment Research

Lala Gregorek

Good things come in threes

Orexo has delivered on three key newsflow items, which should contribute to driving increased Zubsolv use in the treatment of opioid addiction. Submission of Zubsolv’s MAA with the EMA means that first launch ex-US could come from 2018 onwards. FDA approval of a new low dose provides greater dosing flexibility. Positive data from the RESOLV real world study will be leveraged in educating new and existing prescribers to improve their treatment programmes. Ahead of Q316 results we maintain our SEK5.13bn (SEK149/share) valuation highlighting that uncertainty due to the ongoing Actavis litigation continues to weigh on the share price; resolution is expected in H216.

07/10/2016 3 EN

Underlying

Orexo AB

Orexo is a pharmaceutical company and engaged in the development and commercialization of drugs based on patented drug delivery technologies primarily in Sweden and the United States. Co.'s product portfolio includes Zubsolv® tablets for maintenance treatment of opioid dependence; Abstral® for the treatment of breakthrough pain in cancer patients; Edluar®, an active substance zolpidem and for the treatment of short-term insomnia; Diabact UBT, which is used to diagnose the presence of Helicobacter pylori, a bacterium that causes gastric ulcers; and Heliprobe System, which is a doctor's office test to detect the presence of the gastric ulcer bacterium, Helicobacter pylori.

See profile

SE0000736415 Nasdaq Nordic Stockholm Sweden

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Lala Gregorek

Other Reports on these Companies

SmartInsider

Orexo AB: 2 directors

Two Directors at Orexo AB bought 26,370 shares at between 15.386SEK and 15.471SEK. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. ...

Free Trial

November 20, 2023 November 20, 2023 1 EN

ABG Sundal Collier

Orexo - Q3 miss, but no worries

Higher sales and marketing spend resulted in Q3 miss The operational momentum is good Low-risk credit at a decent spread

November 3, 2022 November 3, 2022 1 EN

ABG Sundal Collier

Orexo - Progress is being made

Q2 was fairly in line Progress being made for reimbursements of DTs We remain comfortable with the credit

August 1, 2022 August 1, 2022 1 EN

International Public Partnerships - Consistently and responsibly delivering

International Public Partnerships’ (INPP’s) FY23 results show that it continues to deliver consistent and predictable returns for investors, while delivering environmental and social benefits for the individuals and communities that are served by its assets. Despite this strong performance and a substantial need for private infrastructure funding, the macroeconomic environment has weighed on INPP’s share price, in common with the wider sector. Regardless, attractive returns are available from the existing portfolio with opportunities for further enhancement.

4h / 43m 4h / 43m 1 EN

Kate Heseltine

Kate Heseltine

Portobello SpA - Focus back on the operations

Portobello’s FY23 results demonstrate the primary effects of the out-of-court settlement with respect to VAT and direct taxes (a higher year-end net debt position) and the secondary effects, such as disruption to its trading activities due to management’s focus on cash generation and the company’s inability to trade as previously expected. Following the period end, two capital raises totalling €12.6m, including €3.8m by three of the executive management team, from a maximum mandated amount of €20m, have improved the company’s financial position. The requirement to improve the balance sheet fur...

5h / 26m 5h / 26m 1 EN

Kate Heseltine

Kate Heseltine

Intralot - Focus on business development in FY24

Intralot enjoyed good underlying trends in performance in FY23 with encouraging trends in its main countries of focus and further progress on profitability. The much-improved balance sheet and extension of debt maturities mean management can focus on the significant business development opportunities available in FY24 and beyond. The share price looks attractive in the absence of potential new contract wins, which could be materially enhancing to the valuation.

10h / 40m 10h / 40m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN